tirzepatide in the news outperforms semaglutide weight loss for overweight and obese adults SURPASS-CVOT: Tirzepatide Significantly Reduces Major

2.2 GIPR agonism serves to reduce GLP-1R mediated GI AEs in the clinic Treatment with GLP-1R agonists can drive nausea, diarrhea, vomiting, and constipation, which often results in discontinuation of treatment (6-10% of patients) or reduction in dose (~15% of patients) (63)

Care-quality depth Provider quality is not limited to the checkout page

Ghrelin agonists

Complex patent protections and manufacturing challenges will likely delay generic versions until at least 2032

Lotiglipron was an oral GLP-1-RA contender with a once-a-day treatment that was seen as a viable contender to Ozempic

However, its important to note that Semaglutide (Ozempic) isnt just for people with Type 2 diabetes